High Evidence (L1-L2)
Candidates that may be prioritised for clinical evaluation
Criteria
| Level | Definition | Clinical meaning |
|---|---|---|
| L1 | Multiple Phase 3 RCTs / systematic reviews | Strong support; clinical use may be considered |
| L2 | Single RCT or multiple Phase 2 trials | Moderate support; validation trials can be designed |
L1 (42 drugs)
| Drug | Indications | Link |
|---|---|---|
| Acetylcysteine | 10 | View report |
| Ambrisentan | 10 | View report |
| Anastrozole | 6 | View report |
| Aripiprazole | 10 | View report |
| Atomoxetine | 10 | View report |
| Atorvastatin | 6 | View report |
| Azathioprine | 10 | View report |
| Busulfan | 10 | View report |
| Carboplatin | 10 | View report |
| Celecoxib | 10 | View report |
| Chloramphenicol | 9 | View report |
| Clonidine | 10 | View report |
| Docetaxel | 10 | View report |
| Emicizumab | 10 | View report |
| Ezetimibe | 4 | View report |
| Goserelin | 3 | View report |
| Haloperidol | 10 | View report |
| Ifosfamide | 10 | View report |
| Insulin Aspart | 10 | View report |
| Insulin Glulisine | 10 | View report |
| Ipilimumab | 2 | View report |
| Laronidase | 2 | View report |
| Letrozole | 10 | View report |
| Medroxyprogesterone Acetate | 10 | View report |
| Mercaptopurine | 10 | View report |
| Obinutuzumab | 3 | View report |
| Olaparib | 1 | View report |
| Paclitaxel | 10 | View report |
| Pantoprazole | 6 | View report |
| Pegaspargase | 10 | View report |
| Pertuzumab | 10 | View report |
| Rifabutin | 10 | View report |
| Risperidone | 6 | View report |
| Rosuvastatin | 10 | View report |
| Salmeterol | 7 | View report |
| Sertraline | 8 | View report |
| Simvastatin | 8 | View report |
| Tacrolimus | 3 | View report |
| Temozolomide | 2 | View report |
| Tolvaptan | 10 | View report |
| Trimethoprim | 2 | View report |
| Vancomycin | 10 | View report |
L2 (43 drugs)
| Drug | Indications | Link |
|---|---|---|
| Albendazole | 3 | View report |
| Arsenic Trioxide | 10 | View report |
| Atezolizumab | 10 | View report |
| Beclomethasone Dipropionate | 1 | View report |
| Bedaquiline | 10 | View report |
| Bimatoprost | 10 | View report |
| Calcitriol | 7 | View report |
| Clozapine | 10 | View report |
| Eltrombopag | 1 | View report |
| Everolimus | 10 | View report |
| Fosfomycin | 10 | View report |
| Iloprost | 9 | View report |
| Imiquimod | 10 | View report |
| Lamotrigine | 9 | View report |
| Latanoprost | 10 | View report |
| Lenalidomide | 6 | View report |
| Lenvatinib | 10 | View report |
| Levocarnitine | 10 | View report |
| Lomustine | 10 | View report |
| Magnesium Hydroxide | 6 | View report |
| Mefenamic Acid | 8 | View report |
| Methylprednisolone | 10 | View report |
| Midazolam | 1 | View report |
| Moclobemide | 2 | View report |
| Montelukast | 5 | View report |
| Mycophenolate Mofetil | 10 | View report |
| Oxaliplatin | 4 | View report |
| Paliperidone | 10 | View report |
| Pemetrexed | 10 | View report |
| Pimecrolimus | 4 | View report |
| Pravastatin | 9 | View report |
| Prednisolone | 10 | View report |
| Prednisolone Acetate | 10 | View report |
| Propranolol | 6 | View report |
| Sirolimus | 10 | View report |
| Sunitinib | 10 | View report |
| Temazepam | 1 | View report |
| Tenoxicam | 10 | View report |
| Ticagrelor | 10 | View report |
| Trastuzumab | 10 | View report |
| Trastuzumab Emtansine | 4 | View report |
| Ustekinumab | 10 | View report |
| Vinorelbine | 10 | View report |
Disclaimer
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)